Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s

Background. It is unclear whether the integrase inhibitor raltegravir (RAL) reduces inflammation and immune activation compared with ritonavir-boosted protease inhibitors (PIs). Methods. In a prospective, randomized, multicenter clinical trial that included 328 human immunodeficiency type 1 (HIV-1)–...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Infect Dis
Main Authors: Kelesidis, Theodoros, Tran, Thuy Tien T., Stein, James H., Brown, Todd T., Moser, Carlee, Ribaudo, Heather J., Dube, Michael P., Murphy, Robert, Yang, Otto O., Currier, Judith S., McComsey, Grace A.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2015
Assuntos:
HIV/AIDS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4542595/
https://ncbi.nlm.nih.gov/pubmed/25904376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ327
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares